1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
JEOL Ltd.

JEOL Ltd.

6,848.00
JPY
-48.00
(-0.70%)
278.52BMarket Cap
Nov 13Next Earn
JEOL Ltd.
TSE:6951
(Tokyo Stock Exchange)

Recent

price

6,848.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
1,922.88
2,125.17
2,034.23
2,493.97
1,974.01
2,222.28
2,063.48
2,164.38
2,303.5
2,426.74
2,285.72
2,781.73
3,187.36
3,413.14
3,847.49
3,511.01
- -
Revenue per Share
1.33
-231.19
40.82
100.03
41.21
84.63
12.31
93.8
122.95
110.92
77.51
246.76
349.32
424.92
365.55
432.57
- -
Basic EPS, GAAP
47.49
35.25
-182.22
11.62
152.24
110.19
-66.05
99.6
67.68
17.3
-75.98
423.83
-59.52
231.53
368.54
17.72
- -
Free Cash Flow per Basic Share
7.05
8
0.08
12.83
11.03
9.96
13.99
13.99
18.07
24.2
24.19
26.19
66.34
69.35
113.39
115.65
- -
Dividend per Share
607.01
363.9
506.59
595.88
630.23
664.11
668.22
773.83
860.85
933.03
1,055.47
1,684.05
1,995.48
2,456.99
2,672.15
2,975.22
2,975.22
Book Value per Share
563.56
318.99
466.94
496.19
544.23
590.03
605.47
719.44
814.32
824.51
980.53
1,617.31
1,940.8
2,412.56
2,598.32
2,874.71
2,874.71
Tangible Book Value per Share
39
39
39
40
48
48
48
48
48
48
48
50
51
51
51
51
51
Basic Weighted Avg Shares
75,274
83,191
79,629
99,331
95,379
107,373
99,698
104,570
111,289
117,243
110,439
138,408
162,689
174,336
196,695
179,353
- -
Sales/Revenue/Turnover
1.36
-1.41
3.73
6.07
3.07
5.72
2.08
3.76
5.99
6
4.73
10.22
14.85
15.79
18.05
14.51
- -
Operating Margin (%)
3,167
2,890
2,276
2,619
3,086
3,245
2,894
3,037
3,124
3,560
4,216
4,334
4,922
4,747
5,178
5,510
- -
Depreciation Expense
52
-9,050
1,598
3,984
1,991
4,089
595
4,532
5,940
5,359
3,745
12,278
17,830
21,704
18,688
22,097
- -
Net Income, GAAP
165.08
- -
17.62
10.47
43.02
29.12
73.79
5.5
20.95
28.06
33.29
26.26
24.81
26.35
25.13
25.06
- -
Effective Tax Rate (%)
0.07
-10.88
2.01
4.01
2.09
3.81
0.6
4.33
5.34
4.57
3.39
8.87
10.96
12.45
9.5
12.32
- -
Profit Margin (%)
16,227
7,088
11,586
25,664
26,114
26,780
33,011
30,775
33,167
35,585
41,402
67,692
78,154
81,754
96,497
91,083
91,083
Working Capital
14,182
8,678
9,002
15,469
16,110
12,221
18,610
13,537
10,603
12,914
17,618
11,754
7,106
8,348
4,297
9,234
9,234
LT Debt
24,046
14,388
19,830
28,792
30,451
32,087
32,285
37,387
41,591
45,078
50,998
85,903
101,892
125,513
136,651
144,897
144,897
Total Equity
-1.02
- -
4.33
8.57
2.48
6.66
0.86
5.87
8.3
7.22
4.32
10.8
16.03
15.22
17.74
11.89
- -
Return on Invested Capital (%)
-0.16
- -
3.92
7.22
3.43
6.84
1.1
7.62
9.75
8.02
4.87
13.21
16.45
17.03
13.08
13.96
- -
Return on Capital (%)
0.21
-47.62
9.38
16.39
6.72
13.08
1.85
13.01
15.04
12.37
7.8
17.94
18.99
19.09
14.26
15.7
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
3,709
17,868
LT Borrowings
- -
1,392
7,903
LT Finance Leases
- -
- -
1,331
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
49
Market Capitalization
225,273
260,056
278,522

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
161,762
170,545
Cash, Cash Equivalents & STI
- -
36,027
38,949
Accounts Receivable, Net
- -
41,168
50,503
Inventories
- -
79,803
75,529
Total Current Liabilities
- -
70,413
79,462
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,709
17,868
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.43%
25.03%
6.03%
Free Cash Flow
-237.03%
-262.8%
-95.2%
Net Income, GAAP
86.65%
59.83%
18.24%
Sales/Revenue/Turnover
5.78%
10.81%
-8.82%
Total Cash Common Dividend
- -
48.3%
1.91%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28,671
40,047
38,159
67,459
174,336
2025
- -
- -
- -
- -
196,695
2026
- -
- -
- -
- -
179,353

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33.76
113.38
51.48
226.25
424.92
2025
- -
- -
- -
- -
365.55
2026
- -
- -
- -
- -
432.57

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
69.35
2025
- -
- -
- -
- -
113.39
2026
- -
- -
- -
- -
115.65
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
JEOL Ltd. JEOL Ltd. engages in the research, development, manufacture, marketing, and servicing of scientific and metrology instruments, semiconductor equipment, industrial equipment, and medical equipment; core offerings encompass electron optics instruments including transmission electron microscopes, scanning electron microscopes, and cryo-electron microscopes, analytical instruments such as nuclear magnetic resonance spectrometers and mass spectrometers, measuring instruments, electron beam lithography systems for semiconductors, plasma devices and electron beam metal 3D printers for industrial applications, as well as clinical chemistry analyzers, rack handlers, and laboratory information systems in the medical segment. The company, founded in 1949 and headquartered in Akishima, Tokyo, Japan, operates globally with significant presence in the United States, China, Europe, and other regions, serving markets in materials science, life sciences, semiconductors, drug discovery, batteries, nanotechnology, and environmental monitoring through subsidiaries and sales networks. Recent developments include the acquisition of Japan Superconductor Technology, Inc. from Kobe Steel finalized in early 2025 to bolster superconducting wire and magnet capabilities for enhanced competitiveness in growth areas, a partnership agreement with WEGO Shingene Medical Technology Co., Ltd. signed in March 2025, the disposal of its clinical chemistry testing business to Sysmex Corporation via a share transfer set for completion in April 2026, and enhancements to its stock compensation system involving treasury share disposals for directors and executives.

Company News

Company News APIChatGPT

  • defenseworld.net

    JEOL Ltd. (OTCMKTS:JELLF) Sees Significant Increase in Short Interest